Total revenue for Q1 2025 was $81.7 million, including $75.9 million in net product sales. FILSPARI sales accounted for the majority, demonstrating substantial sequential and year-over-year growth.

Learn about side effects, cost, uses, and more of Filspari (sparsentan), which is a prescription drug that helps manage IgA nephropathy in adults.

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI ...

FILSPARI should generally be avoided in patients with elevated aminotransferases (>3x ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25. If approved, FILSPARI could be the first and only approved medicine ...

So far, Filspari’s launch has been going well. The drug brought in $27.1 million in sales in the second quarter of the year, coming 37% above the prior quarter and ahead of analysts’ consensus ...

Since Filspari's trial data suggests it's superior to Irbesartan, its market might be larger in the long run. For context, Irbesartan's market is projected to grow to $2.9 billion by 2031.

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in ...

Filspari, an endothelin and angiotensin II receptor antagonist, had previously received accelerated approval for IgA nephropathy based on clinical trial data indicating a reduction of proteinuria.

Six months after Travere Therapeutics’ Filspari won an accelerated nod to treat patients with a rare kidney disease, the first-of-its-kind drug narrowly failed its confirmatory trial. While the ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure. Travere Therapeutics, Inc. ...